Johnson & Johnson has moved a step closer to filing a potential first-in-class therapy for psoriasis after the drug hit the mark in a phase 3 trial. Once-daily oral IL-23 inhibitor icotrokinra (fo ...
Regulations 2015 we are pleased to inform you that the Meeting of the Board of Directors of the Company is scheduled to be held on Thursday February 13th 2025 at House no 12 Plot no 6a Ground floor- ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback